Early effects of IL-6 receptor inhibition on bone homeostasis: A pilot study in women with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 29, Issue 6, 2011, Pages 921-925

  Terpos, Evangelos ^a,b   Fragiadaki, Kalliopi ^a   Konsta, Maria ^a   Bratengeier, Cornelia ^c   Papatheodorou, Athanassios ^b   Sfikakis, Petros P ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Biomarker Design Forschungs GmbH   (Austria)

Author keywords

Dickkopf 1; Receptor activator of nuclear factor kappaB ligand (RANKL); Sclerostin; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; DICKKOPF 1 PROTEIN; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PREDNISOLONE; SCLEROSTIN; TOCILIZUMAB;

ADULT; ARTICLE; BONE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HOMEOSTASIS; HUMAN; PILOT STUDY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS;

ADULT; ALKALINE PHOSPHATASE; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; COLLAGEN TYPE I; DRUG THERAPY, COMBINATION; FEMALE; GENETIC MARKERS; HOMEOSTASIS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; METHOTREXATE; OSTEOCALCIN; OSTEOGENESIS; OSTEOPROTEGERIN; PEPTIDES; PILOT PROJECTS; PREDNISOLONE; RANK LIGAND; RECEPTORS, INTERLEUKIN-6;

EID: 84857534016     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. DE BENEDETTI F, RUCCI N, DEL FATTORE A et al.: Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006;54:3551-63. (Pubitemid 44737167)
2. WONG PK, QUINN JM, SIMS NA, VAN NIEUWENHUIJZE A, CAMPBELL IK, WICKS IP: Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigeninduced arthritis and drives inflammation induced osteoclastogenesis. Arthritis Rheum 2006;54:158-68. (Pubitemid 43122198)
3. AXMANN R, BÖHM C, KRÖNKE G, ZWERINA J, SMOLEN J, SCHETT G: Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 2009;60:2747-56.
4. IIASHIZUME M, HAYAKAWA N, MIHARA M: IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford) 2008;47:1635-40.
5. HEILAND GR, ZWERINA K, BAUM W et al.: Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 2010;69:2152-9.
6. LOOTS GG, KNEISSEL M, KELLER H et al.: Genomic deletion of a long-range bone enhancer misregulates sclerostin in van Buchem disease. Genome Res 2005;15:928-35. (Pubitemid 40994212)
7. MIHARA M, KASUTANI K, OKAZAKI M et al.: Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Immunopharmacol 2005;5:1731-40. (Pubitemid 41116745)
8. POLYZOS SA, ANASTASILAKIS AD, BRATEN-GEIER C et al.: Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women - The six-month effect of risedronate and teriparatide. Osteoporosis Int 2011 Jan 11 (Epub ahead of print).
9. GONZÁLEZ-ALVARO I, ORTIZ AM, TOMERO EG et al.: Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1675-8. (Pubitemid 350205461)
10. KERSCHAN-SCHINDL K, WENDLOVA J, KUDLACEK S et al.: Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in healthy women and men. Exp Clin Endocrinol Diabetes 2008;116:491-5.
11. GEUSENS PP, LANDEWÉ RB, GARNERO P et al.: The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006;54:1772-7. (Pubitemid 43877926)
12. HAYNES D, CROTTI T, WEEDON H et al.: Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome. Arthritis Rheum 2008;59:911-20. (Pubitemid 351990986)
13. GARNERO P, THOMPSON E, WOODWORTH T, SMOLEN JS: Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 2010;62:33-43.
14. GARNERO P, TABASSI NC, VOORZANGER-ROUSSELOT N: Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. J Rheumatol 2008;35:2313-5.
15. DAOUSSIS D, LIOSSIS SN, SOLOMOU EE et al.: Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010;62:150-8.
16. CATRINA AI, AF KLINT E, ERNESTAM S et al.: Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 2006;54:76-81. (Pubitemid 43122189)
17. WAKABAYASHI H, OKA H, NISHIOKA y et al.: Do biologies-naïve patients with rheumatoid arthritis respond better to tocilizumab than patients for whom anti-TNF agents have failed? A retrospective study. Clin Exp Rheumatol 2011;29:314-7.